BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

XTL Biopharmaceuticals Ltd. (XTLB) Successfully Completes a Capital Raise in Israel of Approximately $3.5 Million Led by Institutional Investors


3/19/2012 10:33:15 AM

HERZELIYA, Israel, March 19, 2012 /PRNewswire/ --

$1.1 million was raised by way of exercise of tradable warrants at NIS 1.05 per share ($0.56 per ADR).

$2.4 million was raised in a lock-up private placement at a share price of NIS 0.79 per share ($0.42 per ADR).

The raise will enable acceleration of the clinical development programs of the Company.

XTL Biopharmaceuticals (TASE: XTL, OTC: XTLBY) announced yesterday, March 18, 2012, it successfully completed a private placement of securities with foreign as well as Israeli institutional and private investors for a total of $2.4 million (NIS 9.1 million). The placement will have a 6-month lock-up period. Furthermore, the Company raised an additional approximate $1.1 million (NIS 4.2 million) by way of exercise of tradable warrants (series 2) at NIS 1.05 per share ($0.56 per ADR).

The private placement together with the warrants' exercise totalled to approximately $3.5 million (approximately NIS 13.3 million). Menora Mivtahim Underwriting and Management Ltd. acted as an advisor for the private placement.

"We are happy to announce the completion of the raising, led by key institutional investors" mentioned Ronen Twito, XTL's Chief Financial Officer, and added "the completion of the raising and its character demonstrate the investors' belief in the Company, and will enable the Company to mark the US capital markets as a target in the near future."

David Grossman, XTL's Chief Executive Officer said "We would like to thank the investors and our shareholders for their investment and support in the Company. The raising will enable us to accelerate our development programs and expand our drug development pipeline."

About XTL Biopharmaceuticals, Ltd.

XTL Biopharmaceuticals, Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of clinical unmet needs. The Company is focused on late stage clinical development of drugs for the treatment of multiple myeloma, schizophrenia, and hepatitis C.

The Company's lead drug candidate, rHuEPO for the treatment of multiple myeloma blood cancer was granted an orphan drug designation from the FDA. rHuEPO has been approved for marketing by the FDA and has been sold for many years, totalling billions of dollars in sales across the world for the treatment of severe anemia.

XTL is a public company traded on the Tel Aviv Stock Exchange (TASE: XTL) and its ADRs are quoted in the US on the Pink Sheets (OTC: XTLBY).

For further details, please contact:

XTL Investor Relations, Tel: +972-9-955-7080 or email: ir@xtlbio.com


SOURCE XTL Biopharmaceuticals Ltd



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES